US5889136A
(en)
|
1995-06-09 |
1999-03-30 |
The Regents Of The University Of Colorado |
Orthoester protecting groups in RNA synthesis
|
EP2386637B1
(en)
*
|
2001-09-28 |
2018-05-16 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Microrna molecules
|
US7683036B2
(en)
*
|
2003-07-31 |
2010-03-23 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
|
US20050261217A1
(en)
|
2004-05-18 |
2005-11-24 |
Isis Pharmaceuticals Inc. |
Modulation of pumilio 1 expression
|
US7825229B2
(en)
|
2005-03-25 |
2010-11-02 |
Rosetta Genomics Ltd. |
Lung cancer-related nucleic acids
|
US7592441B2
(en)
|
2004-10-04 |
2009-09-22 |
Rosetta Genomics Ltd |
Liver cancer-related nucleic acids
|
US7642348B2
(en)
|
2004-10-04 |
2010-01-05 |
Rosetta Genomics Ltd |
Prostate cancer-related nucleic acids
|
US20070259349A1
(en)
|
2006-05-04 |
2007-11-08 |
Itzhak Bentwich |
Bladder cancer-related nucleic acids
|
ES2534304T3
(en)
|
2004-11-12 |
2015-04-21 |
Asuragen, Inc. |
Procedures and compositions involving miRNA and miRNA inhibitor molecules
|
JP2008539731A
(en)
|
2005-05-02 |
2008-11-20 |
コールド スプリング ハーバー ラボラトリー |
Compositions and methods for diagnosis and treatment of cancer
|
WO2006133022A2
(en)
|
2005-06-03 |
2006-12-14 |
The Johns Hopkins University |
Compositions and methods for decreasing microrna expression for the treatment of neoplasia
|
EP2377559A1
(en)
|
2005-06-03 |
2011-10-19 |
Southern Adelaide Health Service - Flinders Medical Centre |
Targeting cells with altered microRNA expression
|
CN103820562B
(en)
|
2005-08-01 |
2015-05-13 |
俄亥俄州立大学研究基金会 |
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
|
EP2796554A3
(en)
*
|
2005-09-12 |
2014-12-10 |
The Ohio State University Research Foundation |
Compositions for use in treating BCL2-associated cancers
|
US7670840B2
(en)
|
2006-01-05 |
2010-03-02 |
The Ohio State University Research Foundation |
Micro-RNA expression abnormalities of pancreatic, endocrine and acinar tumors
|
ES2544713T3
(en)
|
2006-01-05 |
2015-09-03 |
The Ohio State University Research Foundation |
MicroRNA based methods and compositions for the diagnosis and treatment of solid cancers
|
EP2514433B1
(en)
|
2006-01-05 |
2015-10-21 |
The Ohio State University Research Foundation |
MicroRNA-based methods for the diagnosis, prognosis and treatment of lung cancer
|
ES2448491T3
(en)
|
2006-03-02 |
2014-03-14 |
The Ohio State University Research Foundation |
MicroRNA expression profile associated with pancreatic cancer
|
AU2007227423B2
(en)
|
2006-03-20 |
2013-11-07 |
The Ohio State University Research Foundation |
MicroRNA fingerprints during human megakaryocytopoiesis
|
EP2261333B1
(en)
|
2006-04-03 |
2016-03-30 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
|
JP5814505B2
(en)
|
2006-04-03 |
2015-11-17 |
ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising antimiRNA antisense oligonucleotide
|
US20080076674A1
(en)
|
2006-07-06 |
2008-03-27 |
Thomas Litman |
Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
|
EP2436786B1
(en)
|
2006-07-13 |
2014-04-16 |
The Ohio State University Research Foundation |
MIR-10a for diagnosing poor survival prognosis colon adenocarcinoma.
|
WO2008014008A2
(en)
|
2006-07-28 |
2008-01-31 |
The Johns Hopkins University |
Compositions and methods for modulating angiogenesis
|
WO2008036741A2
(en)
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
Mir-200 regulated genes and pathways as targets for therapeutic intervention
|
AU2007299873A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Asuragen, Inc. |
miR-143 regulated genes and pathways as targets for therapeutic intervention
|
US8188255B2
(en)
|
2006-10-20 |
2012-05-29 |
Exiqon A/S |
Human microRNAs associated with cancer
|
WO2008046911A2
(en)
|
2006-10-20 |
2008-04-24 |
Exiqon A/S |
Novel human micrornas associated with cancer
|
EP3536788A1
(en)
|
2006-12-21 |
2019-09-11 |
QIAGEN GmbH |
Microrna target site blocking oligos and uses thereof
|
WO2008074328A2
(en)
|
2006-12-21 |
2008-06-26 |
Exiqon A/S |
Microrna target site blocking oligos and uses thereof
|
EP2124967A4
(en)
|
2007-01-26 |
2011-01-05 |
Rosetta Genomics Ltd |
Compositions and methods for treating hematopoietic malignancies
|
US20100310583A1
(en)
|
2007-01-31 |
2010-12-09 |
Immune Disease Institute |
Let-7 microrna and mimetics thereof as therapeutics for cancer
|
US9006206B2
(en)
|
2007-02-27 |
2015-04-14 |
Rosetta Genomics Ltd. |
Composition and methods for modulating cell proliferation and cell death
|
US8399248B2
(en)
|
2007-05-03 |
2013-03-19 |
Merck Sharp & Dohme Corp. |
Methods of using MIR34 as a biomarker for TP53 functional status
|
AU2008275877B2
(en)
*
|
2007-07-18 |
2015-01-22 |
The Regents Of The University Of Colorado, A Body Corporate |
Differential expression of microRNAs in nonfailing versus failing human hearts
|
US20100249213A1
(en)
|
2007-09-06 |
2010-09-30 |
The Ohio State University Research Foundation |
MicroRNA Signatures in Human Ovarian Cancer
|
US8361714B2
(en)
*
|
2007-09-14 |
2013-01-29 |
Asuragen, Inc. |
Micrornas differentially expressed in cervical cancer and uses thereof
|
EP2190992B1
(en)
|
2007-09-14 |
2013-04-03 |
The Ohio State University Research Foundation |
Mirna expression in human peripheral blood microvesicles and uses thereof
|
US20090136957A1
(en)
|
2007-09-15 |
2009-05-28 |
Irena Ivanovska |
Methods and compositions for regulating cell cycle progression via the miR-106B family
|
CA2702241A1
(en)
|
2007-10-11 |
2009-04-16 |
The Ohio State University Research Foundation |
Methods and compositions for the diagnosis and treatment of esophageal adenocarcinomas
|
CN101980712B
(en)
|
2007-10-29 |
2015-02-18 |
雷古拉斯治疗公司 |
Targeting microRNAs for the treatment of liver cancer
|
US20110009469A1
(en)
|
2007-12-05 |
2011-01-13 |
The Johns Hopkins University |
Compositions and methods of treating neoplasia
|
ES2600165T3
(en)
|
2008-02-28 |
2017-02-07 |
The Ohio State University Research Foundation |
MiR-32 antagonists to increase the response of prostate cancer to apoptosis
|
WO2009120712A2
(en)
|
2008-03-24 |
2009-10-01 |
New York University |
Compositions and methods for diagnosing and treating melanoma
|
US20090253780A1
(en)
|
2008-03-26 |
2009-10-08 |
Fumitaka Takeshita |
COMPOSITIONS AND METHODS RELATED TO miR-16 AND THERAPY OF PROSTATE CANCER
|
US20100113284A1
(en)
|
2008-04-04 |
2010-05-06 |
Alexander Aristarkhov |
Small interfering rna (sirna) target site blocking oligos and uses thereof
|
US20090258928A1
(en)
|
2008-04-08 |
2009-10-15 |
Asuragen, Inc. |
Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
|
US20110166200A1
(en)
|
2008-04-24 |
2011-07-07 |
Zhan Zhang |
Methods of using mir210 as a biomarker for hypoxia and as a therapeutic agent for treating cancer
|
US20110212021A1
(en)
|
2008-05-30 |
2011-09-01 |
Slack Frank J |
Targeted oligonucleotide compositions for modifying gene expression
|
US20110071215A1
(en)
|
2008-06-02 |
2011-03-24 |
Harvey Pass |
Compositions and methods for diagnosis, prognosis and treatment of mesothelioma
|
US8927207B2
(en)
*
|
2008-06-05 |
2015-01-06 |
Research Foundation Of State University Of New York |
miRNAs as therapeutic targets in cancer
|
WO2009153774A2
(en)
|
2008-06-17 |
2009-12-23 |
Rosetta Genomics Ltd. |
Compositions and methods for prognosis of ovarian cancer
|
EP2310507A4
(en)
|
2008-07-08 |
2013-03-20 |
David Gladstone Inst |
Methods and compositions for modulating angiogenesis
|
WO2010006111A2
(en)
|
2008-07-10 |
2010-01-14 |
Merck & Co., Inc. |
Methods of using compositions comprising mir-192 and/or mir-215 for the treatment of cancer
|
WO2010023658A2
(en)
|
2008-08-28 |
2010-03-04 |
Rosetta Genomics Ltd. |
Compositions and methods for the treatment of glioblastoma
|
US8153606B2
(en)
|
2008-10-03 |
2012-04-10 |
Opko Curna, Llc |
Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1
|
WO2010065630A2
(en)
|
2008-12-03 |
2010-06-10 |
The Johns Hopkins University |
Compositions and methods for treating hepatic neoplasia
|
EP2370580B1
(en)
|
2008-12-04 |
2019-09-11 |
CuRNA, Inc. |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
|
WO2010065671A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
|
RU2746478C2
(en)
|
2008-12-04 |
2021-04-14 |
КьюРНА, Инк. |
Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene
|
WO2010065156A1
(en)
|
2008-12-05 |
2010-06-10 |
The Ohio State University Research Foundation |
Microrna-based methods and compositions for the diagnosis and treatment of ovarian cancer
|
US20100311815A1
(en)
|
2009-02-23 |
2010-12-09 |
The Regents Of The University Of Michigan |
Mir-101 cancer markers
|
US20100233704A1
(en)
*
|
2009-02-25 |
2010-09-16 |
Cepheid |
Methods of detecting lung cancer
|
CA2754749C
(en)
|
2009-03-04 |
2019-04-30 |
Opko Curna, Llc |
Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt1
|
WO2010104796A2
(en)
|
2009-03-09 |
2010-09-16 |
The J. David Gladstone Institutes |
Methods of modulating smooth muscle cell proliferation and differentiation
|
US20120087992A1
(en)
*
|
2009-03-20 |
2012-04-12 |
Jingfang Ju |
miRNAS AS THERAPEUTIC TARGETS IN CANCER
|
WO2010115050A2
(en)
*
|
2009-04-01 |
2010-10-07 |
The Regents Of The University Of California |
Embryonic stem cell specific micrornas promote induced pluripotency
|
KR101758667B1
(en)
*
|
2009-04-29 |
2017-07-18 |
아카데미쉬 메디쉬 센트륨 |
Means and methods for counteracting, preventing and/or determining heart failure, or a risk of heart failure
|
CA2760589C
(en)
|
2009-05-01 |
2019-08-20 |
Joseph Collard |
Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
|
KR101722541B1
(en)
|
2009-05-06 |
2017-04-04 |
큐알엔에이, 인크. |
Treatment of tristetraproline(ttp) related diseases by inhibition of natural antisense transcript to ttp
|
KR100998365B1
(en)
*
|
2009-06-29 |
2010-12-06 |
압타바이오 주식회사 |
Novel guanosine rich modified oligonucleotides and antiproliferative activity thereof
|
WO2011014980A1
(en)
|
2009-08-07 |
2011-02-10 |
Capitalbio Corporation |
Methods and compositions diagnosing cervical cancer and cervical dysplasia, guidding subsequent treatment, determining prognosis, and improving patient survival
|
WO2011021177A2
(en)
|
2009-08-19 |
2011-02-24 |
Rosetta Genomics Ltd. |
Compositions and methods for prognosis and treatment of prostate cancer
|
WO2011024157A1
(en)
|
2009-08-23 |
2011-03-03 |
Rosetta Genomics Ltd. |
Nucleic acid sequences related to cancer
|
US9157080B2
(en)
|
2009-09-09 |
2015-10-13 |
New York University |
Compositions and methods for treatment, diagnosis and prognosis of mesothelioma
|
WO2011057003A2
(en)
*
|
2009-11-04 |
2011-05-12 |
Samuil Umansky |
Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
|
KR101823702B1
(en)
|
2009-12-16 |
2018-01-30 |
큐알엔에이, 인크. |
Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
|
CA2785177C
(en)
|
2009-12-29 |
2019-09-24 |
Curna, Inc. |
Treatment of tumor protein 63 (p63) related diseases by inhibition of natural antisense transcript to p63
|
WO2011082409A2
(en)
|
2010-01-04 |
2011-07-07 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
|
US8846631B2
(en)
|
2010-01-14 |
2014-09-30 |
Regulus Therapeutics Inc. |
MicroRNA compositions and methods
|
RU2611192C2
(en)
|
2010-01-25 |
2017-02-21 |
Курна, Инк. |
TREATMENT OF RNase H1 RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO RNase H1
|
US8962586B2
(en)
|
2010-02-22 |
2015-02-24 |
Curna, Inc. |
Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcript to PYCR1
|
ES2631458T3
(en)
*
|
2010-03-04 |
2017-08-31 |
Interna Technologies B.V. |
MRNA molecule defined by its source and its therapeutic uses in cancer associated with EMT
|
WO2011113030A2
(en)
|
2010-03-11 |
2011-09-15 |
H.Lee Moffitt Cancer Center & Research Institute |
Human cancer micro-rna expression profiles predictive of chemo-response
|
WO2011116152A2
(en)
|
2010-03-16 |
2011-09-22 |
Sanford -Burnham Medical Research Institute |
Delivery of agents using interfering nanoparticles
|
TWI644675B
(en)
|
2010-04-09 |
2018-12-21 |
可娜公司 |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
US20130131148A1
(en)
|
2010-04-12 |
2013-05-23 |
Noam Shomron |
Micro-rna for cancer diagnosis, prognosis and therapy
|
TWI531370B
(en)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
|
AR081209A1
(en)
|
2010-05-19 |
2012-07-04 |
Opko Curna Llc |
TREATMENT OF DISEASES RELATED TO PROTEIN 11 OF TYPE LYMPHOMA 2 OF CELLS B, (BCL2, BCL2L11) BY INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPT TO BCL2L11
|
US8895528B2
(en)
|
2010-05-26 |
2014-11-25 |
Curna, Inc. |
Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
|
WO2011157294A1
(en)
|
2010-06-16 |
2011-12-22 |
Universita' Degli Studi Di Padova |
Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto
|
WO2012009347A2
(en)
|
2010-07-12 |
2012-01-19 |
Opko Curna Llc |
Treatment of bcl2 binding component 3 (bbc3) related diseases by inhibition of natural antisense transcript to bbc3
|
US9333218B2
(en)
*
|
2010-07-15 |
2016-05-10 |
Emory University |
MicroRNA compositions and methods related thereto
|
WO2012014190A2
(en)
|
2010-07-25 |
2012-02-02 |
New York University |
Compositions and methods for prognosis of mesothelioma
|
US8980549B2
(en)
|
2010-08-01 |
2015-03-17 |
Ramot At Tel Aviv University Ltd. |
MicroRNA patterns for the diagnosis, prognosis and treatment of melanoma
|
CN103210086B
(en)
|
2010-10-06 |
2017-06-09 |
库尔纳公司 |
NEU4 relevant diseases are treated by suppressing the natural antisense transcript of sialidase 4 (NEU4)
|
KR101343616B1
(en)
|
2010-10-08 |
2013-12-20 |
연세대학교 산학협력단 |
Pharmaceutical Compositions for Treating Pancreatic Cancer and Screening Method for Pancreatic Cancer Therapeutic Agent
|
EP2638163B1
(en)
|
2010-11-12 |
2017-05-17 |
The General Hospital Corporation |
Polycomb-associated non-coding rnas
|
WO2012082821A2
(en)
|
2010-12-15 |
2012-06-21 |
Medimmune, Llc |
Melanoma treatments
|
AU2011352036A1
(en)
*
|
2010-12-31 |
2013-07-18 |
Anthrogenesis Corporation |
Enhancement of placental stem cell potency using modulatory RNA molecules
|
US8883757B2
(en)
|
2011-01-03 |
2014-11-11 |
Rosetta Genomics Ltd. |
Compositions and methods for treatment of ovarian cancer
|
EP2474617A1
(en)
*
|
2011-01-11 |
2012-07-11 |
InteRNA Technologies BV |
Mir for treating neo-angiogenesis
|
CN103459598B
(en)
*
|
2011-02-03 |
2016-08-10 |
米尔纳医疗股份有限公司 |
The synthesis analogies of MIR-124
|
US9132152B2
(en)
|
2011-02-10 |
2015-09-15 |
The Regents Of The University Of California |
Compositions and methods for generating induced pluripotent stem cells
|
EP2686448A4
(en)
|
2011-03-18 |
2015-08-05 |
Baylor Res Inst |
Changes in the expression of mir-200c/141 cluster of micrornas as biomarkers for epithelial-to-mesenchymal transition in human colorectal cancer metastasis
|
US8987224B2
(en)
*
|
2011-08-05 |
2015-03-24 |
Baylor College Of Medicine |
MicroRNA-198 as a tumor suppressor in pancreatic cancer
|
US20150267193A1
(en)
*
|
2011-10-14 |
2015-09-24 |
Ramanuj Dasgupta |
MicroRNAs and Methods of Using Same
|
US9745578B2
(en)
|
2011-11-30 |
2017-08-29 |
Cedars-Sinai Medical Center |
Targeting microRNA miR-409-3P to treat prostate cancer
|
JP2015504847A
(en)
|
2011-11-30 |
2015-02-16 |
シーダーズ−サイナイ メディカル センター |
Targeting microRNAs MIR-409-5P, MIR-379, and MIR-154 * to treat prostate cancer bone metastases and drug resistant lung cancer
|
US20140363469A1
(en)
*
|
2012-01-19 |
2014-12-11 |
Alnylam Pharmaceuticals, Inc. |
Viral attenuation and vaccine production
|
KR20140136488A
(en)
|
2012-03-15 |
2014-11-28 |
큐알엔에이, 인크. |
Treatment of brain derived neurotrophic factor(bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
US20150211004A1
(en)
*
|
2012-04-20 |
2015-07-30 |
Agency For Science, Technology And Research |
Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies
|
CA2873766A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating atp2a2 expression
|
BR112014028645A2
(en)
|
2012-05-16 |
2017-06-27 |
Rana Therapeutics Inc |
compositions and methods for modulating expression of apoa1 and abca1.
|
KR102028784B1
(en)
|
2012-05-16 |
2019-10-04 |
트랜슬레이트 바이오 인코포레이티드 |
Compositions and methods for modulating gene expression
|
WO2013173605A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating pten expression
|
CN104583399A
(en)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
Compositions and methods for modulating hemoglobin gene family expression
|
WO2013173645A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating utrn expression
|
CN104583402A
(en)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
Compositions and methods for modulating MECP2 expression
|
SG11201407483YA
(en)
|
2012-05-16 |
2014-12-30 |
Rana Therapeutics Inc |
Compositions and methods for modulating smn gene family expression
|
WO2013173601A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating bdnf expression
|
US9758785B2
(en)
|
2012-07-12 |
2017-09-12 |
Baylor College Of Medicine |
miR-520 microRNAs sensitize cancers to platinum-based therapy
|
US9096853B2
(en)
*
|
2012-09-24 |
2015-08-04 |
U.S. Department Of Veterans Affairs |
Modified siRNA molecules incorporating 5-fluoro-2′-deoxyuridine residues to enhance cytotoxicity
|
ES2782825T3
(en)
|
2012-10-31 |
2020-09-16 |
Univ Rockefeller |
Metastatic Colon Cancer Treatment
|
EP3800256A1
(en)
|
2012-11-06 |
2021-04-07 |
InteRNA Technologies B.V. |
Combination to be used in therapeutic use against diseases or conditions associated with melanoma, or in diseases or conditions associated with activated b-raf pathway
|
WO2014100252A1
(en)
*
|
2012-12-18 |
2014-06-26 |
University Of Washington Through Its Center For Commercialization |
Methods and compositions to modulate rna processing
|
WO2014186462A1
(en)
*
|
2013-05-15 |
2014-11-20 |
The Research Foundation For The State University Of New York |
Microrna-129 as a biomarker for colorectal cancer
|
CA2914536A1
(en)
|
2013-06-07 |
2014-12-11 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating foxp3 expression
|
US20150151004A1
(en)
*
|
2013-06-14 |
2015-06-04 |
The University Of Kansas |
Methods and compositions of modulating tumor initiating cells and the use thereof
|
WO2015066034A1
(en)
*
|
2013-10-28 |
2015-05-07 |
Icahn School Of Medicine At Mount Sinai |
Compositions and methods for modulating neuronal excitability and motor behavior
|
US20160312301A1
(en)
|
2013-12-20 |
2016-10-27 |
The Feinstein Institute For Medical Research |
Microrna biomarkers for ovarian cancer
|
EP3105327A4
(en)
|
2014-02-12 |
2017-10-18 |
Thomas Jefferson University |
Compositions and methods of using microrna inhibitors
|
KR101596166B1
(en)
|
2014-10-07 |
2016-02-19 |
가톨릭대학교 산학협력단 |
A Use of microRNA for Ddiagnosing and Treating Brest Cancer
|
WO2016149455A2
(en)
|
2015-03-17 |
2016-09-22 |
The General Hospital Corporation |
The rna interactome of polycomb repressive complex 1 (prc1)
|
WO2017021963A1
(en)
|
2015-08-03 |
2017-02-09 |
Biokine Therapeutics Ltd. |
Cxcr4 binding agents for treatment of diseases
|
US10053696B2
(en)
|
2016-01-21 |
2018-08-21 |
University Of South Carolina |
MiRNA-489 in treatment of breast cancer
|
AU2017353907B2
(en)
|
2016-11-01 |
2023-11-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
US11236337B2
(en)
|
2016-11-01 |
2022-02-01 |
The Research Foundation For The State University Of New York |
5-halouracil-modified microRNAs and their use in the treatment of cancer
|
US10443055B2
(en)
|
2016-12-22 |
2019-10-15 |
Beth Israel Deaconess Medical Center |
Compounds that target MYC microRNA responsive elements for the treatment of MYC-associated cancer
|
US10988766B2
(en)
|
2017-01-06 |
2021-04-27 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
EP3571212B1
(en)
|
2017-01-23 |
2024-03-06 |
Trustees of Boston University |
Methods relating to lung cancer
|
KR101953300B1
(en)
|
2018-06-22 |
2019-02-28 |
의료법인 성광의료재단 |
A composition, kit and method for diagnosing and treating taxane-based anticancer drugs resistance cancer
|
MA53669A
(en)
|
2018-09-20 |
2021-07-28 |
Modernatx Inc |
COMPOSITIONS AND METHODS OF NUCLEIC ACID DELIVERY
|
WO2020102142A1
(en)
|
2018-11-13 |
2020-05-22 |
Regulus Therapeutics Inc. |
Microrna compounds and methods for modulating mir-10b activity
|
WO2020154207A1
(en)
|
2019-01-22 |
2020-07-30 |
Research Institute At Nationwide Children's Hospital |
A novel method for monitoring and treating oral cancer
|
KR20210139237A
(en)
|
2019-03-14 |
2021-11-22 |
더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 |
Modified microRNAs and their use in the treatment of cancer
|
EP4058152A1
(en)
|
2019-11-14 |
2022-09-21 |
The Board of Regents of the University of Oklahoma |
Oligonucleotide interference treatments of prostate cancer
|
US11965162B2
(en)
|
2020-04-16 |
2024-04-23 |
The Johns Hopkins University |
MicroRNA and inhibitors thereof and methods of treatment
|
WO2021262919A2
(en)
|
2020-06-26 |
2021-12-30 |
The Research Foundation For The State University Of New York |
5-halouracil-modified micrornas and their use in the treatment of cancer
|